Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2012

View Archived Issues

TOCA therapy increases survival in models of brain cancer

Sanofi prepares novel fibroblast growth factor receptor antagonists

Zalicus and Hydra Biosciences to collaborate on ion channel modulators

Washington University study reveals mechanisms behind AML relapse

Phase IIb data on iferanserin support ongoing phase III study

Algeta reports updated data from phase III ALSYMPCA trial

FDA warns of drug interactions with Victrelis

FDA warns for increased risk of CDI-associated diarrhea with proton pump inhibitor use

Pergamum completes recruitment in PXL-01 study

Zealand Pharma to receive milestone payment following completion of GetGoal program

FDA issues draft guidance to assist industry in developing biosimilar products

Dainippon Sumitomo Pharma updates progress of third quarter of fiscal 2011

Santarus commences study of Uceris added to 5-ASA therapy

Advinus Therapeutics and Celgene Global Health enter collaboration

Large phase II trial assesses meningococcal vaccine in infants

Pfizer launches Inlyta in U.S.

Insmed to proceed with clinical studies of Arikace in U.S. and Europe

Kaken Pharmaceutical patents new ADAM inhibitors

U.S. university designs new siRNA products for Sjogren's syndrome

Dicerna Pharmaceuticals patents new RNA-based products

New anticancer products developed

Zhe-Jiang Beta Pharma presents novel PARP-1 inhibitors

Bayer reports novel candidate cancer therapeutics

Novartis receives response from FDA regarding Menveo sBLA

UCB Pharma enters collaboration with Nodality

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...